237 related articles for article (PubMed ID: 26471360)
1. Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer.
Moughon DL; He H; Schokrpur S; Jiang ZK; Yaqoob M; David J; Lin C; Iruela-Arispe ML; Dorigo O; Wu L
Cancer Res; 2015 Nov; 75(22):4742-52. PubMed ID: 26471360
[TBL] [Abstract][Full Text] [Related]
2. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.
Conway JG; McDonald B; Parham J; Keith B; Rusnak DW; Shaw E; Jansen M; Lin P; Payne A; Crosby RM; Johnson JH; Frick L; Lin MH; Depee S; Tadepalli S; Votta B; James I; Fuller K; Chambers TJ; Kull FC; Chamberlain SD; Hutchins JT
Proc Natl Acad Sci U S A; 2005 Nov; 102(44):16078-83. PubMed ID: 16249345
[TBL] [Abstract][Full Text] [Related]
4. Systemic and Cardiac Depletion of M2 Macrophage through CSF-1R Signaling Inhibition Alters Cardiac Function Post Myocardial Infarction.
Leblond AL; Klinkert K; Martin K; Turner EC; Kumar AH; Browne T; Caplice NM
PLoS One; 2015; 10(9):e0137515. PubMed ID: 26407006
[TBL] [Abstract][Full Text] [Related]
5. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.
Chalmers SA; Wen J; Shum J; Doerner J; Herlitz L; Putterman C
Clin Immunol; 2017 Dec; 185():100-108. PubMed ID: 27570219
[TBL] [Abstract][Full Text] [Related]
6. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Khabele D; Yull F
Mol Cancer; 2015 Nov; 14():192. PubMed ID: 26552746
[TBL] [Abstract][Full Text] [Related]
7. Treatment With the CSF1R Antagonist GW2580, Sensitizes Microglia to Reactive Oxygen Species.
Soto-Diaz K; Vailati-Riboni M; Louie AY; McKim DB; Gaskins HR; Johnson RW; Steelman AJ
Front Immunol; 2021; 12():734349. PubMed ID: 34899694
[TBL] [Abstract][Full Text] [Related]
8. Macrophage depletion ameliorates nephritis induced by pathogenic antibodies.
Chalmers SA; Chitu V; Herlitz LC; Sahu R; Stanley ER; Putterman C
J Autoimmun; 2015 Feb; 57():42-52. PubMed ID: 25554644
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic Consequences of Malignant Ascites in Epithelial Ovarian Cancer Surgery*: A Prospective Substudy of a Randomized Controlled Trial.
Hunsicker O; Fotopoulou C; Pietzner K; Koch M; Krannich A; Sehouli J; Spies C; Feldheiser A
Medicine (Baltimore); 2015 Dec; 94(49):e2108. PubMed ID: 26656336
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.
Colombo N; Mangili G; Mammoliti S; Kalling M; Tholander B; Sternas L; Buzenet G; Chamberlain D
Gynecol Oncol; 2012 Apr; 125(1):42-7. PubMed ID: 22112608
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.
Zhao H; Li X; Chen D; Cai J; Fu Y; Kang H; Gao J; Gao K; Du N
Med Oncol; 2015 Feb; 32(2):292. PubMed ID: 25609006
[TBL] [Abstract][Full Text] [Related]
12. [Avastin combined with cisplan inhibits malignant ascites production in nude mice bearing transplanted ovary carcinoma with high VEGF expression].
Cai YJ; Zheng DY; Luo RC; Chen JZ; Li AM; Xi JL; Ding XM
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):647-9. PubMed ID: 17545079
[TBL] [Abstract][Full Text] [Related]
13. PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression.
Prat M; Coulson K; Blot C; Jacquemin G; Romano M; Renoud ML; AlaEddine M; Le Naour A; Authier H; Rahabi MC; Benmoussa K; Salon M; Parny M; Delord JP; Ferron G; Lefèvre L; Couderc B; Coste A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586764
[TBL] [Abstract][Full Text] [Related]
14. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.
Yukita A; Asano M; Okamoto T; Mizutani S; Suzuki H
Anticancer Res; 2000; 20(1A):155-60. PubMed ID: 10769648
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells.
Liu L; Wang X; Li X; Wu X; Tang M; Wang X
Oncol Rep; 2018 Feb; 39(2):818-826. PubMed ID: 29251331
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
[TBL] [Abstract][Full Text] [Related]
17. Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.
Szender JB; Emmons T; Belliotti S; Dickson D; Khan A; Morrell K; Khan ANMN; Singel KL; Mayor PC; Moysich KB; Odunsi K; Segal BH; Eng KH
Gynecol Oncol; 2017 Sep; 146(3):491-497. PubMed ID: 28624153
[TBL] [Abstract][Full Text] [Related]
18. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.
Glass EB; Hoover AA; Bullock KK; Madden MZ; Reinfeld BI; Harris W; Parker D; Hufnagel DH; Crispens MA; Khabele D; Rathmell WK; Rathmell JC; Wilson AJ; Giorgio TD; Yull FE
BMC Cancer; 2022 May; 22(1):497. PubMed ID: 35513776
[TBL] [Abstract][Full Text] [Related]
19. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
[TBL] [Abstract][Full Text] [Related]
20. TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.
Rafehi S; Ramos Valdes Y; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
Endocr Relat Cancer; 2016 Mar; 23(3):147-59. PubMed ID: 26647384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
